Amgen (AMGN) : Summit Capital Management scooped up 11,337 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 153,278 shares of Amgen which is valued at $23.4 Million.Amgen makes up approximately 10.54% of Summit Capital Management’s portfolio.
Other Hedge Funds, Including , Essex Financial Services reduced its stake in AMGN by selling 50 shares or 0.09% in the most recent quarter. The Hedge Fund company now holds 53,112 shares of AMGN which is valued at $8.1 Million. Amgen makes up approx 1.99% of Essex Financial Services’s portfolio.Autus Asset Management reduced its stake in AMGN by selling 86 shares or 5.59% in the most recent quarter. The Hedge Fund company now holds 1,452 shares of AMGN which is valued at $221,212. Amgen makes up approx 0.05% of Autus Asset Management’s portfolio.First National Trust Co reduced its stake in AMGN by selling 828 shares or 2.31% in the most recent quarter. The Hedge Fund company now holds 34,965 shares of AMGN which is valued at $5.3 Million. Amgen makes up approx 0.82% of First National Trust Co’s portfolio.Cadence Bank Na boosted its stake in AMGN in the latest quarter, The investment management firm added 248 additional shares and now holds a total of 3,177 shares of Amgen which is valued at $486,685. Amgen makes up approx 0.25% of Cadence Bank Na’s portfolio.Duff Phelps Investment Management Co reduced its stake in AMGN by selling 2,355 shares or 18.95% in the most recent quarter. The Hedge Fund company now holds 10,070 shares of AMGN which is valued at $1.5 Million. Amgen makes up approx 0.02% of Duff Phelps Investment Management Co’s portfolio.
Amgen opened for trading at $152.35 and hit $153.86 on the upside on Monday, eventually ending the session at $153.27, with a gain of 0.60% or 0.92 points. The heightened volatility saw the trading volume jump to 24,15,093 shares. Company has a market cap of $115,139 M.
On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.
Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.